EUVIMEDEUVIMED entdecken
Fallbericht

Daratumumab for Treatment of Acute Antibody‐Mediated Rejection in a Pediatric Kidney Transplant Recipient

Hailey Connolly iD, Ally Watson iD, Michael Wynd, Kenneth Lieberman iD, Melissa Chaung, Michael J Goldstein iD, Guillermo Hidalgo iD, Ibrahim Batal iD, Marlene Amoruso iD, Namrata G Jain iD

Pediatric Transplantation · 2025-08 · 29 (5)

DOI: 10.1111/petr.70116 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Pediatric Transplantation, online erschienen am 09.06.2025. Verfasst von Hailey Connolly und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Nephrology, Department of Pediatrics, Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center, Hackensack…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Graft Rejection, Kidney Transplantation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Daratumumab, an anti‐CD38 monoclonal antibody, has shown efficacy as a potential treatment for antibody‐mediated rejection (ABMR) following kidney transplantation in adults.

Methods

We present a case demonstrating the use of daratumumab for the management of ABMR in a pediatric kidney transplant recipient.

Results

The patient underwent a living‐unrelated donor renal transplant with a post‐transplant course complicated by active ABMR. The patient received a total of four daratumumab infusions with a subsequent decrease in serum creatinine, serum donor‐specific antibody levels, and donor‐derived cell‐free DNA (dd‐cfDNA), which remained low 1 year following treatment.

Conclusions

Daratumumab may be a promising treatment consideration for the management of ABMR in pediatric patients following renal transplantation, though further research is needed to better understand its efficacy and side effects. DD‐cfDNA may also be a promising tool to monitor treatment response in conjunction with more traditional methods.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalGraft RejectionKidney TransplantationChildHumansTreatment Outcome

Stichwörter der Autor:innen

antibody‐mediated rejectiondaratumumabkidney transplantationpediatrics

Substanzen

Antibodies, Monoclonaldaratumumab

Autor:innen und Institutionen

  • Division of Pediatric Nephrology, Department of Pediatrics, Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center, Hackensack, New Jersey, USA.
  • Division of Transplant Surgery, Hackensack University Medical Center, Hackensack, New Jersey, USA.
  • Division of Pediatric Nephrology, Department of Pediatrics, Jersey Shore University Medical Center, New Jersey, USA.
  • Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA.

ORCID-Profile: Hailey Connolly, Ally Watson, Kenneth Lieberman, Michael J Goldstein, Guillermo Hidalgo, Ibrahim Batal, Marlene Amoruso, Namrata G Jain

Zitieren

APA

Connolly, H., Watson, A., Wynd, M., Lieberman, K., Chaung, M., Goldstein, M. J., Hidalgo, G., Batal, I., Amoruso, M., & Jain, N. G. (2025). Daratumumab for Treatment of Acute Antibody‐Mediated Rejection in a Pediatric Kidney Transplant Recipient. Pediatric Transplantation, 29(5). https://doi.org/10.1111/petr.70116

Vancouver

Connolly H, Watson A, Wynd M, Lieberman K, Chaung M, Goldstein MJ, et al. Daratumumab for Treatment of Acute Antibody‐Mediated Rejection in a Pediatric Kidney Transplant Recipient. Pediatric Transplantation. 2025;29(5). doi:10.1111/petr.70116

BibTeX
@article{Connolly2025,
  author = {Connolly, Hailey and Watson, Ally and Wynd, Michael and Lieberman, Kenneth and Chaung, Melissa and Goldstein, Michael J and Hidalgo, Guillermo and Batal, Ibrahim and Amoruso, Marlene and Jain, Namrata G},
  title = {Daratumumab for Treatment of Acute Antibody‐Mediated Rejection in a Pediatric Kidney Transplant Recipient},
  journal = {Pediatric Transplantation},
  year = {2025},
  volume = {29},
  number = {5},
  doi = {10.1111/petr.70116}
}
Kostenlos starten →